Heron Therapeutics, Inc. (NASDAQ:HRTX) Short Interest Update

Heron Therapeutics, Inc. (NASDAQ:HRTX - Get Free Report) saw a significant growth in short interest during the month of April. As of April 30th, there was short interest totalling 27,290,000 shares, a growth of 7.3% from the April 15th total of 25,430,000 shares. Based on an average daily volume of 2,350,000 shares, the days-to-cover ratio is presently 11.6 days.

Analysts Set New Price Targets

A number of research firms have issued reports on HRTX. Capital One Financial began coverage on Heron Therapeutics in a research note on Tuesday, April 23rd. They issued an "overweight" rating and a $6.00 target price on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $5.00 price objective on shares of Heron Therapeutics in a research report on Thursday.

Heron Therapeutics Stock Up 7.3 %

HRTX stock traded up $0.22 during trading on Thursday, reaching $3.22. 4,045,139 shares of the company's stock were exchanged, compared to its average volume of 2,745,917. Heron Therapeutics has a 1-year low of $0.50 and a 1-year high of $3.23. The company's fifty day moving average price is $2.75 and its 200-day moving average price is $2.16. The firm has a market cap of $485.09 million, a PE ratio of -5.21 and a beta of 1.73.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last released its earnings results on Tuesday, March 12th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.08. The firm had revenue of $34.23 million during the quarter, compared to analyst estimates of $30.98 million. As a group, sell-side analysts expect that Heron Therapeutics will post -0.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Heron Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC bought a new position in Heron Therapeutics during the third quarter valued at approximately $31,000. Commonwealth Equity Services LLC raised its holdings in shares of Heron Therapeutics by 5.5% during the 3rd quarter. Commonwealth Equity Services LLC now owns 314,826 shares of the biotechnology company's stock valued at $324,000 after purchasing an additional 16,467 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Heron Therapeutics by 5.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 353,395 shares of the biotechnology company's stock valued at $364,000 after purchasing an additional 19,345 shares during the last quarter. Jacob Asset Management of New York LLC boosted its holdings in Heron Therapeutics by 18.2% in the third quarter. Jacob Asset Management of New York LLC now owns 327,450 shares of the biotechnology company's stock worth $337,000 after purchasing an additional 50,435 shares in the last quarter. Finally, Richmond Brothers Inc. increased its position in Heron Therapeutics by 142.9% during the third quarter. Richmond Brothers Inc. now owns 103,009 shares of the biotechnology company's stock worth $106,000 after buying an additional 60,604 shares during the last quarter. Institutional investors and hedge funds own 80.01% of the company's stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.